DOvEE
Diagnosing Ovarian & Endometrial Cancer Early
Thousands of Canadian women are diagnosed with ovarian and endometrial cancers each year. Together, these two killers are the fourth-highest cause of all cancer cases and cancer deaths in Canadian women. And yet, cure rates haven’t improved in over 30 years. A breakthrough led by the MUHC’s Dr. Lucy Gilbert promises to radically reduce this threat to women’s lives. But the DOvEE Project needs both financial support and women to participate in its final clinical trial.
What if you could be a part of this solution?
DOvEE celebrates milestone
Dr. Lucy Gilbert is one step closer to saving countless women’s lives thanks to over $2 million raised in support of the DOvEEgene test. On April 5th, donors, volunteers and DOvEE Project personnel gathered to celebrate this triumph for women and families everywhere.
DOvEE: New Hope Against A Silent Killer
Gynecologic oncologist Dr. Lucy Gilbert has the answer: the DOvEEgene test. As routine as a pap smear, this minimally invasive test can detect cancer using DNA analysis before it becomes a death sentence. Dr. Gilbert and her team have just begun the final clinical trial of this lifesaving test, and she needs your help to make it a standard of women’s care. It's a historic discovery, made in Quebec. Help Dr. Gilbert ensure there are no more women lost.
Early Diagnosis Is Key
When doctors diagnose ovarian and endometrial cancers early, the cure rate is over 80%. At this point, the cancer is still confined to the reproductive organs. The problem is, 75% of ovarian cancers and 25% of endometrial cancers are diagnosed late. By that time, the disease has spread outside the pelvis. The stats paint a grim picture: when diagnosed late, only 10–30% of women with ovarian or endometrial cancer survive.
Once it has spread, radical surgery and powerful chemotherapy cannot cure it. The best we can do is contain the cancer temporarily. The DOvEEgene test promises to be the world’s first reliable way to diagnose ovarian and endometrial cancers early, when the disease can still be cured.
Clinical trials will establish that the DOvEEgene test is:
- Reliable, simple to use and cost effective
- Comfortable for patients
- Easy to process
- Simple to roll out
The DOvEEgene test promises to do for ovarian and endometrial cancers what the pap smear did for cervical cancer decades ago — move cervical cancer from second to 16th place for cancer deaths in women.
You can help make the difference between life and death.
“Philanthropy – that’s what makes Montreal different. What I find wonderful about Montreal is the sense of community, the civic responsibility, and the philanthropy.”
– Dr. Lucy Gilbert
Join the DOvEEgene Clinical Trial
The DOvEE Project is now actively recruiting anyone with a uterus between 45-75 years of age to join the phase 3 clinical trial being held in Montreal, Quebec. By participating you will be helping this final research phase before Health Canada approval. If you would like to participate or to learn more contact 1-(866)-716-3267.
News
Leadership
Joining us on this campaign are committee members:
- Micol Haimson, Co-chair
- Matthew Marchand, Co-chair
- Joanne Photiades, Co-chair
- Valerie Aitken
- Ilana Cohen
- Justine Frangouli-Argyris
- Paula Gillett
- Esthel Gravel
- Catherine Heaton
- Anne Lafleur
- Houda Moussalier
- Danièle Thibodeau
- Tina Scalia
HELP US STOP THE SILENT KILLER.
For more information, to make a donation or to get involved, please contact Edith Bolduc, Associate Director of Development, Major Gifts, at 514-934-1934, ext. 34397, [email protected]